Women with breast cancer treated with aromatase inhibitors (AIs) are a population in which the coexistence of imbalance of bone and glucose homeostasis, similar to that detected in diabetic patients [34], could represent a model to elucidate the effect of denosumab (Dmab) on glucose metabolism. Here, CYP19A1 is linked to breast carcinoma.